The global diabetes devices market size was valued at USD 23.0 billion in 2019 and is expected to expand at a CAGR of 7.8% during the forecast period. Increasing incidence of diabetes due to rising geriatric population and an increasing number of obesity cases, along with technological advancement in the field of diabetes preventive care are driving the market growth. According to the Centers for Disease Control and Prevention (CDC), 93.3 million people were obese in 2016 and the number is expected to grow further during the forecast period.
Rising awareness about preventive care and technological advancement are among the factors expected to boost market growth. According to the International Diabetes Federation, the global diabetes population is expected to reach 700 million by 2045 from 463 million in 2019. Technological advancement and frequent new product launches are the factors expected to have a propelling effect on the market during the forecast period. In June 2018, Senseonics received FDA approval for its Implantable Eversense Continuous Glucose Monitoring (CGM) system in the United States. This long-term CGM system is one of the important milestones in the technological timeline of diabetes devices. The devices constantly monitor blood glucose levels for 90 days without the use of lancets, thus significantly increasing patient convenience.
Key market players are focusing on developing smart CGM devices, which can give real-time blood glucose reading and help patients take quick decisions. Patients are now using AI-based apps that can connect to these smart blood glucose monitoring devices. Moreover, there are many government initiatives and learning platforms for patient’s requirements. For instance, in June 2019, Informed Data Systems Inc. and One Drop launched a glucose monitoring system along with its one-year unlimited access to certified diabetes coaches. This platform will help patients learn how to use a glucose monitoring system effectively.
Rising healthcare funding by government and private institutions in the field of diabetes care are contributing to constant improvement in novel diabetes management solutions. According to the International Diabetes Federation, North America accounted for 43% of the total diabetes related expenditure globally. In addition, in November 2018, the Australian government announced the funding of USD 100 million to subsidize continuous glucose monitoring products through the National Diabetes Services Scheme.
Based on distribution channels, the market has been segmented into hospital pharmacies, retail pharmacies, diabetes clinics, online pharmacies, and others. The hospital pharmacies segment accounted for the largest market share due to the availability of a variety of products and a rising number of diabetes device sales in these pharmacies.
Furthermore, the online pharmacies segment is expected to register the highest growth rate during the forecast period owing to rising awareness about online shopping and an increasing number of product approvals to sell diabetes devices on online platforms.
By end-use, the diabetes devices market is segmented into hospitals, home care, and diagnostic centers. The hospital segment is dominating the market due to rising healthcare expenditure in hospitals and improving infrastructure. Furthermore, the cost of measuring blood sugar levels in hospitals, with additional capabilities to store and transfer information, is higher than the home-care setting, thus, generating greater revenue for the market.
The home care segment is expected to register the fastest growth rate during the forecast period due to the increasing adoption of self-blood glucose monitoring devices and rising awareness about diabetes preventive care. Furthermore, an increasing number of diabetes patients that require a daily dosage of insulin and rising government initiatives to spread diabetes awareness are some of the factors contributing to market growth.
Based on the product, the market is segmented into Blood Glucose Monitoring (BGM) and insulin delivery devices. Insulin delivery devices accounted for the largest market size owing to the rising adoption of insulin pumps and technological advancement. Insulin delivery devices segment is further divided into pens, pumps, syringes, and jet injectors. Insulin pumps segment is expected to register the highest growth rate owing to technological collaboration and advent of smart insulin pumps. For instance, in June 2019, Medtronic and Tidepool announced the partnership to develop an automated insulin pump system.
BGM devices segment also held considerable market share owing to rising awareness about diabetes devices and technological advancement. BGM devices segment is further divided into Self-monitoring of Blood Glucose (SMBG) devices and continuous blood glucose monitoring devices. Self-monitoring devices accounted for the largest market size owing to its high usage and low cost. Self-monitoring of blood sugar is an approach whereby people measure their blood sugar level with the help of glucose meter. The segment is further segregated into blood glucose meter, testing strips, and lancets. Testing strips segment accounted for the largest market size owing to affordability and easy to use.
CGM segment is expected to grow at the fastest pace during the forecast period due to the advent of smart CGM and technological collaboration. For instance, in January 2019, Medtronic Plc collaborated with Eris Lifesciences to develop a smart continuous glucose monitoring system. The segment is further divided into sensors, transmitters, and receivers. Transmitters segment held the largest market size owing to the high cost of the device and high usage.
Based on region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is dominating the market owing to the presence of a large number of patients and a favorable reimbursement scenario. According to the International Diabetes Federation, in 2019, there were 48 million people in North America suffering from diabetes in 2019, and this number is expected to reach 63 million by 2045. Moreover, increasing FDA approval and product launches are also boosting the market growth in the region. In December 2017, Companion Medical Launched Inpen, its first smart insulin pen system in the U.S., which is the only FDA approved system that can combine insulin injector pen with a smart app.
Asia-Pacific is expected to see significant growth during the forecast period owing to rising favorable policies and awareness drives for advanced diabetes devices. Government initiatives and educational programs are also propelling the market during the forecast period. For instance, Novo Nordisk along with Health Care Community launched an awareness campaign in 2017. The company organized diabetes awareness events across the country and also donated 2 million Yuan. In 2016 federal election, the government of Australia committed to subsidize CGM technology to assist young adults and children under 21 years of age who are facing challenges in dealing with their type 1 diabetes. Diabetes Australia is now providing access to subsidized CGM products through National Diabetes service schemes (NDSS).
Some of the leading players present in the market are Medtronic plc; Abbott Laboratories; F.Hoffmann-La-Ltd.; Bayer AG; Lifescan, Inc.; B Braun Melsungen AG; Lifescan, Inc.; Dexcom Inc.; Insulet Corporation; Ypsomed Holdings; Companion Medical; Sanofi; Valeritas Holding Inc.; Novo Nordisk; and Arkray, Inc. Market leaders are focusing on product launches and technological collaboration to increase their foothold in the market. For instance, in September 2019, Novo Nordisk collaborated with Medtronic Plc., to develop a solution to integrate insulin dosing data from Novo smart insulin pens into CGM devices. The collaboration will help both patients and healthcare professionals to view both glucose and insulin data together.
Base year for estimation
Actual estimates/ Historical data
2016 - 2018
2020 - 2027
Revenue in USD Million and CAGR from 2020 to 2027
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, U.K., Germany, France, Italy, Spain, Czech Republic, Russia, Poland, Turkey, Switzerland, China, Japan, India, Australia, South Korea, Vietnam, Philippines, Malaysia, Indonesia, Thailand, Mexico, Brazil, Colombia, Argentina, Chile South Africa, Saudi Arabia, Oman, Egypt, and UAE
Revenue forecast, company share, competitive landscape, growth factors, and trends
15% free customization scope (equivalent to 5 analysts working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels as well as provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global diabetes devices market report on the basis of product, distribution channel, end use, and region:
Product Outlook (Revenue, USD Million, 2016 - 2027)
Blood Glucose Meter
Continuous Glucose Monitoring Devices
Insulin Delivery Devices
Distribution Channels Outlook (Revenue, USD Million, 2016 - 2027)
Diabetes Clinics/ Centers
End Use Outlook (Revenue, USD Million, 2016 - 2027)
Regional Outlook (Revenue, USD Million, 2015 - 2026)
Middle East & Africa
b. The global diabetes devices market size was estimated at USD 23.0 billion in 2019 and is expected to reach USD 24.6 billion in 2020
b. The global diabetes devices market is expected to grow at a compound annual growth rate of 7.7% from 2019 to 2027 to reach USD 41.5 billion by 2027
b. North America dominated the diabetes devices market with a share of 39.5% in 2019. This is attributable to presence of a large number of patients and favorable reimbursement scenario
b. Some key players operating in the diabetes devices market include Medtronic plc; Abbott Laboratories; F.Hoffmann-La-Ltd.; Bayer AG; Lifescan, Inc.; B Braun Melsungen AG; Lifescan, Inc.; Dexcom Inc.; Insulet Corporation; Ypsomed Holdings; Companion Medical; Sanofi; Valeritas Holding Inc.; Novo Nordisk; and Arkray, Inc.
b. Key factors that are driving the market growth include increasing incidence of diabetes due to rising geriatric population and increasing number of obesity cases, along with technological advancement in the field of diabetes preventive care.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPA norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.